Navigation Links
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Date:5/14/2013

WALTHAM, Mass., May 14, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard treatments, announced today the publication in the Journal of Clinical Oncology of positive results of a phase 2 randomized, double-blind, placebo-controlled study of the company's lead drug entinostat.  The study showed that entinostat extended both progression-free survival and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor.  

"These remarkable results show that adding entinostat, a class I histone deacetylase inhibitor (HDAC) to standard antiestrogen therapy may be an effective, well tolerated approach to targeting resistance pathways in breast cancer, particularly in hormone-positive disease," said lead author Denise A. Yardley , M.D., Senior Investigator, Sarah Cannon Research Institute; Associate, Tennessee Oncology, PLLC. "Additionally, for the first time, we identified a potential biomarker in a subset of patients with estrogen receptor positive tumors that was associated with a greater progression-free survival, which may ultimately offer the potential for improved clinical outcomes with entinostat."

The study evaluated entinostat in 130 postmenopausal women with advanced ER+ breast cancer, progressing on a nonsteroidal aromatase inhibitor. Patients were randomly assigned to 25 mg exemestane daily plus 5 mg entinostat once per week (64 patients), or exemestane plus placebo (66 patients). The primary end point was progression-free survival (PFS); blood was also collected in a subset of patients
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Jazz Pharmaceuticals plc ... will report its 2014 second quarter financial results on ... financial markets.  Company management will host a live audio ... p.m. IST to provide a business and financial update ... Interested parties may access the live audio webcast via ...
(Date:7/22/2014)... 2014  Decision Resources Group finds that the market for ... will remain relatively stagnant at a value of around $80 ... coronary intervention (PCI) volumes are growing faster in ... the United States and ... the increase in penetration of PCI procedures relative to coronary ...
(Date:7/22/2014)... ALBANY, New York , July 22, 2014 ... published by Transparency Market Research "Process Spectroscopy Market (Technology Types ... infrared (FT-IR) spectroscopy) Market - Global Industry Analysis, Size, Share, ... valued at USD 714.5 million in 2012 and is expected ... 2019. North America was ...
Breaking Medicine Technology:Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4
... , , , ... , , BOSTON, July 29 For many women, ... sassy bobs to long, cascading curls, the right hairstyle can make any ... her appearance. That,s why hair loss can be particularly devastating for women, ...
... , , , ... , , HARRISBURG, Pa., July 28 ... quarantined after at least three horses tested positive for the neurologic form ... , , There is no threat to human health ...
Cached Medicine Technology:Is Your Hair Taking a Break? 2Is Your Hair Taking a Break? 3Is Your Hair Taking a Break? 4Is Your Hair Taking a Break? 5Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable 2
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Michael DeBaun, ... Robert P. Hebbel, MD, of the University of Minnesota ... Prize for their significant research advances in the area ... named for the late Ernest Beutler, MD, a past ... years, is a two-part lectureship that recognizes major translational ...
(Date:7/22/2014)... Marc, Ph.D., director of research at the University of ... by the International Society of Eye Research (ISER) as ... 2014 Paul Kayser International Award in Retina Research., The ... has made a significant contribution to the understanding of ... this week at the ISER Biennial Meeting in San ...
(Date:7/22/2014)... D.C. (PRWEB) July 22, 2014 ... “Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
(Date:7/22/2014)... may share certain pathogenic mechanisms with cancer, according to ... Linda Kusner, Ph.D. , published in PLOS ... work shows that the very same inhibitors of apoptosis, ... cells that produce autoimmune diseases. Henry Kaminski, M.D. ... GW School of Medicine and Health Sciences (SMHS), as ...
(Date:7/22/2014)... July 22, 2014 The Beryl Institute ... third annual Institute Scholar Program. These offerings reinforce the ... patient experience in healthcare and the need for rigorous ... grant and scholar programs are intended to ... Value of focusing on the patient experience before, ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3
... Two innovative child welfare toolkits ... Immigrant Families -- A Child Welfare Flowchart (August 2009) ... Immigrant Families -- Immigration Status and Relief Options (June ... protection services (CPS) workers, attorneys, immigration workers and legal aides ...
... , WASHINGTON, Nov. 4 The United States and ... Claims Act suit in the Western District of Virginia ... Marion LLC and Keystone Education and Youth Services LLC, ... the Keystone Marion Youth Center, a residential facility in ...
... PURCHASE, N.Y., Nov. 4 Nutrition 21, Inc. (OTC ... and finished products under the Iceland Health®, Chromax®, and ... levels, improve cardiovascular health, enhance memory and reduce chronic ... quarter of fiscal year 2010 ended September 30, 2009. ...
... condition, it might have a wider application, experts say , ... to treat patients with a rare form of anemia could ... have been linked to an increased risk of death, cancer ... in treating patients who have pure red-cell aplasia, a condition ...
... a protein implicated in rare form of bowel disorder, ... People with painful, chronic bowel conditions such as Crohn,s ... hope from new research. , Scientists say they,ve spotted ... form of colitis, and the finding might have implications ...
... ... Living and Alzheimer’s/Memory Care , ... Neenah, Wis. (Vocus) November 4, 2009 -- Industry innovator CRL Senior Living Communities ... assisted living community, on Thursday, November 19 from 4 to 7 p.m. , , , ...
Cached Medicine News:Health News:Toolkits Available to Child Welfare Workers to Better Handle Immigration-Related Issues 2Health News:Toolkits Available to Child Welfare Workers to Better Handle Immigration-Related Issues 3Health News:Toolkits Available to Child Welfare Workers to Better Handle Immigration-Related Issues 4Health News:United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 2Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 2Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 3Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 4Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 5Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 6Health News:Will New Anemia Drug Top Current Treatments? 2Health News:Will New Anemia Drug Top Current Treatments? 3Health News:Gene Discovery Gives Clues to Crohn's Disease, Colitis 2Health News:Gene Discovery Gives Clues to Crohn's Disease, Colitis 3Health News:Merrill Hills Manor, New Alzheimer's/Memory Care and Assisted Living Community, Welcomes Public to Grand Opening on November 19 in Waukesha 2Health News:Merrill Hills Manor, New Alzheimer's/Memory Care and Assisted Living Community, Welcomes Public to Grand Opening on November 19 in Waukesha 3
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
... the most advanced image-guided platforms available ... of an expandable platform. In addition ... supports new applications in electromagnetics (EM). ... well as the ability to track ...
... The Mayfield 2000 series radiolucent headrest system ... intraoperative digital subtraction angiography. This system is ... skull clamp and the Mayfield radiolucent base ... designed for patient positioning in the prone ...
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Medicine Products: